Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Share-based Compensation data on record, last reported at $1.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation changed N/A year-over-year to $1.0 million; the TTM value through Dec 2025 reached $56.0 million, changed N/A, while the annual FY2025 figure was $60.0 million, 21.05% down from the prior year.
  • Share-based Compensation reached $1.0 million in Q4 2025 per RCUS's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $20.0 million in Q1 2024 and bottomed at $1.0 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $15.8 million, with a median of $17.0 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 268.6% in 2021, then decreased 20.0% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $14.3 million in 2021, then increased by 18.99% to $17.0 million in 2022, then rose by 5.88% to $18.0 million in 2023, then grew by 5.56% to $19.0 million in 2024, then crashed by 94.74% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.0 million in Q4 2025, $16.0 million in Q1 2025, and $19.0 million in Q3 2024.